Paul F. Lizzul - 14 Sep 2023 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
Chief Medical Officer
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
14 Sep 2023
Transactions value $
-$41,005
Form type
4
Filing time
18 Sep 2023, 19:14:49 UTC
Previous filing
10 Jan 2023
Next filing
05 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise +6K +227.96% 8.63K 14 Sep 2023 Direct F1, F2
transaction ANAB Common Stock Sale -$41K -2.11K -24.39% $19.48 6.53K 14 Sep 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Restricted Stock Unit Options Exercise $0 -6K -50% $0.00 6K 14 Sep 2023 Common Stock 6K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 Reflects the acquisition of 881 shares acquired under the Company's ESPP.
F3 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.